文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤抗PD-1治疗时长:多少才算足够?

Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
PubMed 文献 · J Clin Oncol · 2018-02-01

本文以一例53岁男性复发性移行黑色素瘤患者为引,该患者经手术、干扰素及放疗后多次复发,最终接受帕博利珠单抗2 mg/kg每3周治疗。文章围绕抗PD-1治疗的最佳持续时间展开讨论,综述相关文献并总结管理建议,以帮助临床医生将关键研究结果应用于实践。

要点

  • 晚期黑色素瘤抗PD-1治疗的最佳持续时间尚存争议。
  • 病例展示多线治疗后仍出现移行转移,起始帕博利珠单抗治疗。
  • 需结合文献与临床实践个体化决定抗PD-1治疗时长。

核心结论

  • 晚期黑色素瘤抗PD-1治疗的最佳持续时间需进一步明确,临床应个体化决策。

研究设计与样本

  • Oncology Grand Rounds系列文章,以病例展示结合文献综述与管理建议。

主要发现

  • 一例53岁男性复发性移行黑色素瘤患者,经多线治疗后接受帕博利珠单抗2 mg/kg每3周治疗。

临床怎么用

  • 临床医生应结合文献证据与患者具体情况,个体化确定抗PD-1治疗的持续时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 53-year-old healthy man presented with recurrent in-transit melanoma of the right lower extremity. Eight years prior he had undergone wide local excision and sentinel lymph node biopsy for invasive melanoma of the anteromedial aspect of the distal right thigh. Pathology revealed an ulcerated melanoma, Breslow depth 3.5 mm, and with one involved micrometastatic inguinal lymph node. Staging studies did not demonstrate distant metastases. Superficial inguinal node dissection was performed and did not identify any additional metastatic nodes of 14 retrieved for a final pathologic staging of T3bN1aM0 (stage IIIB) cutaneous melanoma. He received 12 months of adjuvant high-dose interferon alfa-2b. Two years later, he developed a 1.2-cm subcutaneous focus of in-transit recurrence approximately 4 cm proximal to the original melanoma site in the right thigh, which was treated with surgical resection followed by adjuvant radiotherapy. Over the next 4 years, he underwent six additional surgeries for isolated in-transit recurrences affecting the same limb. He was referred for therapeutic options at the time of his latest in-transit recurrence. Examination revealed three palpable subcutaneous nodules in the right thigh in the setting of lymphedema. A core biopsy confirmed recurrent melanoma (Fig 1). Whole-body fluorodeoxyglucose positron emission tomography imaging revealed at least 17 hypermetabolic cutaneous and subcutaneous nodules in the right thigh, four fluorodeoxyglucose-avid nodules below the right knee, but no distant metastases (Fig 2A). Brain magnetic resonance imaging was normal. His serum chemistry profile, including lactate dehydrogenase, was normal. Molecular analysis demonstrated presence of BRAF V600E mutation in the tumor. After multidisciplinary evaluation, an isolated limb infusion procedure of the right lower extremity was not believed to be feasible, secondary to the proximal extent of the recurrence. Therapy was initiated with pembrolizumab at 2 mg/kg intravenously every 3 weeks.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Khushalani NI. Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough? J Clin Oncol. 2018. PMID: 29389234. doi:10.1200/JCO.2017.76.8275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。